TrialAtlas is introduced, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk.
Abstract
Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.
The Virtual Biotech is introduced, an organization of artificial intelligence agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development, which demonstrates its utility at three drug-development decision points.
Harrison G. Zhang, P. Eckmann, Jia-Cheng Miao et al.· Science· 0 citations
It is argued that achieving the potential of AI in oncology clinical trials will require rigorous prospective validation, harmonized regulatory standards, and coordination among clinicians, trialists, regulators, industry and patients.
Andrea Villa, A. Eadie, David Synnott et al.· Nature Reviews Clinical Onco...· 0 citations
MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success, is developed.
H. H. Caline Koh-Tan, Ivan Meić, Buğra Alptekin Sarı et al.· bioRxiv· 0 citations
An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov and may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations. In silico clinical...
Maximilian Balmus, Sheng-Ya Wang, Edward W. G. Ashton et al.· Clinical pharmacology and th...· 1 citation
Abstract Clinical artificial intelligence (AI) has advanced rapidly, with frontier large language models now matching or exceeding physician performance on simulated diagnostic reasoning and clinical decision-support tasks. Yet adoption has outpaced the evidence base: fewer than 5% of cleared U.S. Food and Drug Adminis...
J. Worth, Anastasia Perez, David Wu et al.· BMJ digital health & AI· 1 citation
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 19, 2026
An MIT and Dana-Farber Institute-led team used large language models to examine nearly 4,000 studies and hundreds of code repositories, revealing gaps in the information needed to scrutinize and reuse published research.
By studying the computational foundations of language learning, Associate Professor Jacob Andreas builds intelligent systems that can communicate effectively with humans.